Product Description
Mechanisms of Action: Bacterial Growth Inhibitor,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Chile | India | Italy | Malaysia | New Zealand | Portugal | Taiwan | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Jiao Tong University School of Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2400094162 | N/A |
Not yet recruiting |
Unknown |
2028-12-31 |
|
ChiCTR2300067260 | N/A |
Not yet recruiting |
Hypertension |
2026-03-31 |
|
ChiCTR2300070608 | N/A |
Recruiting |
Other |
2025-08-31 |
|
ChiCTR2300070642 | N/A |
Recruiting |
Brain Diseases|Inflammation |
2025-06-30 |